The (PNH) Therapeutics Market is Forecast to Show Slow Growth until 2019

Tuesday 13 March 2012, Amsterdam

The industry analysis specialist, has released its new report, “Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics market. The report identifies the key trends shaping and driving the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics sector.


The Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is Forecast to Show Slow Growth until 2019

They estimates that the Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market in the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan was worth $758.3m in 2011 and is forecast to grow at a compound annual growth rate (CAGR) of 4.8% to reach $1,104m by 2019. The current market is strong and dominated by the only approved drug - Soliris (eculizumab) from Alexion Pharmaceuticals. The growth during 2006-2011 is primarily attributed to the launch of Soliris in 2007 in both the US and Europe. The current treatment option for PNH includes Soliris for hemolysis in PNH patients. Other treatment options include immunosuppressants, recombinant erythropoietin, supportive care therapies and stem cell transplantation. There are no promising industry-sponsored molecules in the late stage developmental pipeline. Therefore, the PNH therapeutics market is expected to show slow growth until 2019.


The Hemolytic PNH Therapeutics Market has Low Unmet Need

The only approved therapy for PNH patients is Soliris, which is approved for the treatment of hemolysis in PNH patients. There is low unmet need in the hemolytic PNH therapeutics market as the drug significantly reduces intravascular hemolysis and reduces the risk of developing thrombotic events by 90%, which is a major cause of mortality among PNH patients.

The availability of this drug influences the other treatment options in the market despite its high cost.


Low Potential for New Entrants in the PNH Therapeutics Market

The PNH therapeutics market is well served by the currently marketed drug as they are highly effective in treating all PNH patients with hemolysis. The non-hemolytic PNH therapeutics market is served moderately by generics and the patients are treated according to the underlying bone marrow failure. Therefore, the PNH therapeutics market does not offer a significant opportunity for new entrants.


Weak Pipeline Unlikely to Drive the Growth of PNH Therapeutics Market

An analysis of the pipeline landscape shows that the late stage pipeline does not offer any immediate new hope for PNH patients. There is no molecule in the late stages of clinical development. The only molecule in Phase II is alemtuzumab, which is under investigation for PNH patient treatment (an allogeneic stem cell transplantation) by the University of Arizona. Alexion Pharmaceuticals has one novel molecule in the pipeline (TT30) but it is still under Phase I clinical development.